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Abstract
Background
Respiratory syncytial virus (RSV) is globally ubiquitous, and infection during the first six
months of life is a major risk for severe disease and hospital admission; consequently RSV
is the most important viral cause of respiratory morbidity and mortality in young children.
Development of vaccines for young infants is complicated by the presence of maternal anti-
bodies and immunological immaturity, but vaccines targeted at older children avoid these
problems. Vaccine development for young infants has been unsuccessful, but this is not the
case for older children (> 6m). Would vaccinating older children have a significant public
health impact? We developed a mathematical model to explore the benefits of a vaccine
against RSV.
Methods and Findings
We have used a deterministic age structured model capturing the key epidemiological char-
acteristics of RSV and performed a statistical maximum-likelihood fit to age-specific hospi-
talization data from a developing country setting. To explore the effects of vaccination under
different mixing assumptions, we included two versions of contact matrices: one from a
social contact diary study, and the second a synthesised construction based on demo-
graphic data. Vaccination is assumed to elicit an immune response equivalent to primary
infection. Our results show that immunisation of young children (5–10m) is likely to be a
highly effective method of protection of infants (<6m) against hospitalisation. The majority
benefit is derived from indirect protection (herd immunity). A full sensitivity and uncertainty
analysis using Latin Hypercube Sampling of the parameter space shows that our results are
robust to model structure and model parameters.
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Conclusions
This result suggests that vaccinating older infants and children against RSV can have a
major public health benefit.
Introduction
Respiratory syncytial virus (RSV) accounts for 66,000–199,000 deaths per year globally [1]. It
causes a major burden of severe lower respiratory tract disease in children under 5yrs of age
with an estimated 3,000,000 hospital episodes annually in all countries [1]. The vast majority of
this burden occurs in low income countries [1]. The age distribution of childhood severe dis-
ease is highly skewed towards young infants (<6m), with around 50% of all RSV associated
hospitalisations in this age group, attributed to small airway blockage through inflammation
and sloughing of infected epithelial cells [2]. Early vaccine development, focused on this vul-
nerable group resulted in disaster when a formalin-inactivated preparation administered to
naïve children led to exacerbated pneumonia and mortality upon natural RSV challenge [3].
Over the subsequent five decades, vaccination research for young infants has centred on live
attenuated virus candidates (e.g. [4, 5]), but progress has been compromised by the presence of
maternally derived antibodies (MAb), immunological immaturity, vaccine intolerance [3], and
the legacy of uncertainty from the early vaccine failure.
Currently, there is a growth of interest in RSV vaccine development due to technical
advances in delivery modalities, with around 45 candidates in various pre-clinical and clinical
stages [6]. At the same time, there is recognition of the need to consider other groups to vacci-
nate to reduce the burden of infant disease. Older children aged 6 to 24 months are one of these
groups—they have the advantage of a more mature immune system, lower levels of interfering
maternal antibody and greater tolerance [7]. Live attenuated virus vaccines (LAV) administered
intranasally to seronegative children of this age have been shown to be both immunogenic and
well tolerated e.g. [4, 5]. Importantly they are also shown not to predispose the child to
enhanced disease following wild type exposure, and, although the trials are small in size, indi-
cated protective efficacy [8]. There is an active clinical trial program for LAV candidates for the
prevention of RSV associated lower respiratory tract infection in young children [6, 9, 10].
The potential impact of vaccination of older children (including groups such as elder siblings)
will depend upon the degree of direct and indirect protection due to the intervention. There are
clear direct benefits to be gained from vaccinating older children since a significant proportion of
RSV severe disease occurs beyond the first 6 months of life [11]. However, the main emphasis
remains the prevention of disease in early infancy, which would have to accrue from indirect pro-
tection (often called herd immunity). Manufacturers and funding agencies would be encouraged
if it were to be shown that vaccinating older infants offered an additional indirect protection to
the young infant. To what extent older age group vaccination will confer herd immunity to the
vulnerable young infant is unclear [12, 13]. This forms the subject of this paper.
Analysis of a cohort study in Kenya has demonstrated that the severe risk in young children
is principally associated with age at infection, not their lack of experience of infection [14].
Studies of transmission in households have shown that at least half of transmission to infants is
due to infection introduced to the household by their older siblings [15, 16]. Both of these
results support the idea that immunisation of older children against RSV could be used to
reduce disease in infants by delaying primary infection until they are older. Vaccination pro-
vides both direct protection to those who are successfully immunized with the vaccine and
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indirect protection for those who are not immunized by decreasing the number of the infec-
tious individuals. Therefore, the impact of immunisation of children on infection and disease
in infants is largely determined by the rate at which infection is transferred between different
risk or age groups [17–19]. Consequently, we explore two different, data-based formulations of
the age-related contact matrix, and also perform a parameter sensitivity analysis.
Our aim is to comprehensively explore the impact of childhood immunisation on RSV
infection and morbidity, in the developing country setting, using mathematical predictive
models paying particular attention to the pattern of mixing between age groups. What is the
impact of vaccination of older infants and children on the public health burden of RSV in
young infants?
Methods
Model
We have developed a deterministic model aimed at simulating the transmission dynamics of
RSV in an age-structured population. The demographic structure subdivides the population
into 99 age classes: 24 monthly age classes in the first two years of life and yearly age classes
from the third year of life. Individuals older than 77 years have been put into the final age class.
The selection of monthly age groups up to 2 years of age is chosen so as to capture the trans-
mission dynamics and the impact of vaccination in the most critical age groups. The number
of people in each age group is allowed to vary through a continuous ageing process and natural
deaths.
Individuals are modelled in 10 mutually exclusive groups as shown in Fig 1. Individuals are
born with temporary but solid maternal immunity (M). We estimate the duration and distribu-
tion of protection by inclusion of a variable number of stages, p, within theM class, all of which
confer full protection. After maternal immunity has waned, individuals enter a fully susceptible
class (S0) and may experience primary infection I0. After each infection, there is a period of
transient solid immunity (P0,P1,P2) before individuals become partially susceptible (S1,S2)
reflecting that multiple infection episodes within epidemics are rare [20, 21]. Previously
infected individuals have reduced susceptibility to infection [22], reduced duration of infection
[23, 24] and reduced infectivity of infection on infection. The incidence of disease (D) is related
to age and episode while hospitalisation (H) is related to age. The rates, with respect to both
time and age at which individuals flow from one epidemiological state to another are described
in the system of ODE shown in Eqn A in S1 File. The infectiousness of second and subsequent
re-infections is parameterized relative to primary infected class. The per capita rate of infection
experienced by individuals in age class a at time t is given by λa(t). As the transmission of RSV
is seasonal, we included a cosine function, fitting both the amplitude (i.e. strength of seasonal-
ity) and phase (i.e. timing). Table 1 gives a description of the parameters and their estimated
values. The initial conditions for the state variables for each age class were taken to be the pre-
vaccination numbers found by running the model for a period of 50 years to its stable limit
cycle. This ensures that the transient population and infection dynamics effects are minimized
during model fitting and vaccination. The set of ODE’s was solved numerically in Matlab
1
[25]
based on an explicit Runge-Kutta method of order (4,5) using an adaptive time step.
Immunisation is assumed to confer protection to individuals such that it protects against
primary infection. This assumption corresponds to the situation for a highly attenuated live
virus vaccine that would not boost antibody titres in seropositive susceptibles [4]. Vaccination
is implemented continuously and moves individuals from S0 to P0 (green line in Fig 1) as they
pass a specified age gate. We consider a single efficacy parameter, coverage, which includes
both the proportion vaccinated and the proportion protected by vaccination. To calculate the
Vaccine Induced Herd Immunity for Control of RSV
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effect of direct protection, we run the model with a time invariant force of infection whose
value is fixed at the pre-vaccination equilibrium.
Data sources and model fitting
The transmission rates between individuals in the model are determined by age-related mixing:
the who-acquires-infection-from-whom (WAIFW) matrix [26, 27]. Because the details of the
age-related mixing are influential and largely unknown, we include two approaches to estimate
Fig 1. Themodel natural history framework. Rectangles represent mutually exclusive states, solid arrows are flows between states and dotted lines show
classes that contribute to the rates of disease (D) and hospitalization (H). The solid green line shows the effect of vaccination, which prevents primary
infection only and otherwise has an action like primary infection.
doi:10.1371/journal.pone.0138018.g001
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WAIFW parameters. First, we use contact data that arise from diary data collected for a ran-
dom sample of individuals who reside within the Kilifi Health and Demographic Surveillance
System (KHDSS) [28, 29] (Fig 2A). Second, we estimate a synthetic contact matrix (Fig 2B) by
weighted combination of three component matrices: a background homogeneous matrix, a
matrix of contacts derived from household structure and a matrix of contacts derived from
school attendance (Fig A in S1 File). The household occupancy data used for this synthetic
matrix also arise from the registers of the KHDSS. Assuming that the WAIFWmatrix is repre-
sented by βij, and the contact matrix by χij, then we link the two by assuming that the self-
reported age-specific number of social contacts are proportional to the age-specific number of
potentially infectious contacts [30], i.e βij = qχij where q is a disease specific infectivity parame-
ter that we estimate by fitting the model to age-specific hospitalisation data.
The hospitalization data was obtained from Kilifi District Hospital (KDH), which is situated
in the Kilifi County in Kenya, and serves as the primary care and referral facility for the pre-
dominantly rural population of the KHDSS [29]. The age specific fertility and mortality data
Table 1. Baseline parameter estimates used in the numerical simulations and the estimates of the fitted parameters.
Parameter Description Baseline value Data source
σk Long-term immunity factor reducing the susceptibility of previously exposed
individuals in S1 and S2
σ1 = 0.75
σ2 = 0.65
[22]
ρk Rate of waning of short-term immunity of recovered individuals ρ0 = ρ1 = ρ2 = 2/
yr
[20, 21]
γ0 Rate of recovery from primary infection, I0 40.6/yr [15, 24]
γ1,γ2 Rate of recovery from secondary and subsequent infections: I1I2 93.7/yr [15, 23]
αk Factor reducing infectiousness of I1 and I2 α1 = 0.5
α2 = 0.25
See text for justiﬁcation
N Population size 240,000 KHDSS**
μα* Age-related death rate Mid-year 2011 estimates from KHDSS** data
κα* Rate of ageing 0−24m = 12/yr
3−77yrs = 1/yr
Reciprocal of the length of the age
class
ω Duration of RSV speciﬁc maternal antibody protection Fitted—see below
PM Number of classes of maternal protection Fitted—see below
ξ Amplitude Fitted—see below
ϕ Phase angle Fitted—see below
q Infectivity parameter—Diary model Fitted—see below
qH,qS,qHS Infectivity parameters—Synthetic model Fitted—see below
Estimated values of ﬁtted parameters
Parameter Diary model (95% CI) Synthetic model (95% CI)
ω 2.3 (1.91 2.69) months 4.04 (3.6 4.5) months
PM 1 1
ξ 0.096 (0.088 0.105) 0.21 (0.19 0.22)
ϕ 8.95e-7 (-0.0082 0.0083) (peak, 01 Jan) 2.216 (2.208 2.223) (peak, 26 March)
q 0.00228 (0.00225 0.0023) -
qH - 102.54 (98.65 106.43)
qS - 15,648 (15,633 15,663)
qHS - 2.56e
-12 (-0.058 0.058)
* The index α represents the age class i.e. α = 1,2,. . .,n where n = 99. PM is the number of M sub-classes such that {PM: 1,2,. . .,P}. The rate of ageing
from age class α is κα. The different infection states are subscripted by k = 0,1,2.
**KHDSS—the Kiliﬁ Health and Demographic Surveillance System [29]
doi:10.1371/journal.pone.0138018.t001
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used in the model were obtained from the KHDSS registers for the mid-year estimates for
2007. The model was fitted to RSV specific monthly admissions to KDH. Surveillance started
in 2002 on all children<5 years admitted in KDH with clinical symptoms of pneumonia, either
severe or very severe. Nasal specimens were collected as soon as possible after admission by
nasal washing and screening for RSV antigen was undertaken using an Immunofluorescent
Antibody Test (IFAT). The data used are the temporal and age-specific hospitalizations from
Oct 2004 to Dec 2010. For more details on the study and the data, please refer to Nokes et al
[11]. The risks of disease following infection are taken from a longitudinal cohort study of RSV
infection in Kilifi, Kenya [14], and given in Table A in S1 File. The age-specific risk of hospitali-
zation was estimated by fitting the static model (model with force of infection that is age-spe-
cific but constant in time) to hospitalization data. The initial vector was estimated from
longitudinal data of RSV infections [12]. Once estimated from the static model, the risk of hos-
pitalization remains fixed for fitting the dynamic model.
We calculate the expected incidence of hospitalisations from infections in two stages: the
age-specific and infection-specific risk of disease given infection (d0,a,d1,a,d2,a), see Table A in
S1 File, and the age-specific risk of hospitalisation given disease (ha), see Table B in S1 File. Eq
1 gives the expected number of hospitalisations from the model and this output is compared to
the KDH hospitalization data during model fitting.
Hða; tÞ ¼ hala
X2
i¼0
di;asi;aSi;a ð1Þ
The model was ﬁtted using statistical maximum-likelihood estimation assuming that the age
and time counts follow a Poisson distribution. We optimized the model parameters by
Fig 2. The estimatedWAIFWmatrices and the fits to hospitalisation data by age and time: left (A,C) are the diary WAIFW results, and right (B,D) are
the synthetic WAIFWmatrix. A) the mean number of contacts per day by participants (Y axis) by age group from a contact diary study in coastal Kenya
corrected for population sizes.B) the fitted combination of three separate matrices for household structure, school attendance and homogeneous mixing
plotted as the logarithm per person rate of contact (see S1 File). C) andD) show the age (top) and time (bottom) summed data (red dots), bootstrapped
confidence intervals (grey bands) and the model fit (blue line) (note that the model was fitted to age-time data).
doi:10.1371/journal.pone.0138018.g002
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maximizing the log-likelihood as shown in Eq 2:
LL ¼
X27
a¼1
XTa
t¼1
ðkða; tÞlogHða; tÞ  Hða; tÞ 
Xkða;tÞ
j¼1 logðjÞÞ
( )
ð2Þ
where k(a,t) is the expected incidence of hospitalizations at age a and time t, Ta is the number
of time points at which the expected incidence data are made for each age a andH(a,t) is the
corresponding expected incidences from the model at each age class a and time t. The negative
log-likelihood was used as the objective function of fmincon, which is a minimization routine
in the computational software Matlab
1
[25]. To calculate the 95% conﬁdence interval of the ﬁt-
ted parameters, we compute the central ﬁnite difference approximation to the Hessian of the
log-likelihood estimates given the observed data to generate an asymptotic covariance matrix,
and use a normal approximation [31]. To generate the bootstrapped conﬁdence interval of the
hospitalization data, we generated subsets, by both time and age, of data from the original set
by sampling with replacement. The 95% conﬁdence interval was taken as the region between
the 97.5th and the 2.5th percentiles. The model output of interest is the proportion of RSV hos-
pitalisations averted based on the long-term post-vaccination equilibrium when vaccination is
implemented at a given age and coverage.
Uncertainty and sensitivity analysis
Due to the structural complexity coupled with a high degree of uncertainty in some of the
model input parameters, we performed global uncertainty and sensitivity analysis. Using Latin
hypercube sampling (LHS) [32], we generated 200 sets of 10 parameters (see Table 2 for the
parameters included, their probability density functions and the lower and upper bounds), for
each of the WAIFWmatrices, making a total of 400 different sets. For each of these sets, the fit-
ted parameters are re-estimated from the age-specific hospitalisation data. We calculated the
partial rank correlation coefficients for each of the input parameters and the model output.
Ethical Review and consent
Kenya Ethics Review Committee (KEMRI/RES/7/3/1) and the Biomedical and Social Ethics
Review Committee of the University of Warwick (134-07-2011) approved the study. Written
informed consent was sought from participants aged18 years and from parents or guardians
of those aged<18 years. The data was analyzed anonymously to generate a Who Acquires
Infection FromWhom (WAIFW) matrix.
Results
Fig 2 shows the twoWAIFWmatrices obtained from the contact diary data (A) and the syn-
thetic contact matrix (B), respectively. Both indicate a strong within age group (assortative)
mixing particularly in the school going age groups and secondary cross-generational mixing
(e.g. parent to child; teacher to pupil), note the difference in the colour axis. The outcome of fit-
ting the model is shown in Fig 2C and 2D. The directly estimated contact patterns and the syn-
thetically estimated WAIFW give results indistinguishable in terms of fit to the hospitalisation
data. The log-likelihood values for the diary and synthetic models were -1481.3895 and
-1443.8595 with basic reproduction number (R0) of 7.08 and 25.60 respectively calculated as
the dominant Eigen values of the WAIFWmatrices [33]. Whilst the model reproduces the
overall pattern, it is unable to predict the variation between different epidemics, which might
be due to shifting viral genetics [34]. Similarly, the age groups within the mixing matrices do
Vaccine Induced Herd Immunity for Control of RSV
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not match those in the data, which might explain the slight over-estimation in the 4–6m age
groups.
Fig 3 shows the proportion of hospitalisations prevented, for different combinations of cov-
erage (proportion immunised) and age of immunisation. Vaccination is potentially effective if
given after maternal immunity is lost and before individuals have been infected for the first
time. The predicted impact for the contact diary is higher, and maximum impact is more
broadly distributed, resulting from a less peaked force of infection in infancy (see Fig 4C and
4D).
Fig 4A shows the short-term temporal effects of vaccination on the number of hospitalisa-
tions with immunisation implemented at time 0 at 6 months at 70% coverage. The diary model
predicts a honeymoon period [35] of approximately 6 years before equilibrating to yearly epi-
demics with an alternating pattern of low and high peaks. On the other hand, the synthetic
model does not predict a change in the pattern except that the epidemic peaks are reduced. Fig
4B shows that the total vaccine effect (solid lines) is much greater than the direct effect alone
(dashed lines)–the difference is the indirect effect of protection of younger infants from infec-
tion. Fig 4C and 4D show the age-specific force of infection at equilibrium for the dairy and the
synthetic models respectively. The solid lines shows pre-vaccination force of infection and the
dashed lines show the force of infection with vaccination at 6 months at 70% coverage. It is
clear from the figure that individuals aged between 2 and 20 years of age dominate the force of
infection for the synthetic model. This can be attributed to the high number of contacts occur-
ring within and between those age groups in the household. Immunisation is expected to
change the average age at infection and this is shown in Fig 4E. This figure shows the change in
the average age at primary (solid lines) and secondary (dashed lines) infections with a vaccine
given at 6 months and for different vaccination coverages. The average age at primary infection
increases from about 2 to 9 years (at 100% coverage) for the diary model (blue solid line) while
the synthetic model predicts a relatively small increase, 2 to 2.5 years (red solid line).
We then used LHS to explore the effects of uncertainty in estimating the values of the input
variables on the prediction precision on the optimal age at vaccination, in particular exploring
the range of potential optimum ages predicted. Fig 5A shows the proportion of RSV hospital
cases averted at 70% coverage at different ages. There is considerable heterogeneity in the suc-
cess of the vaccination programme depending on the assumed parameters: the bars show the
range excluding the highest and lowest 2.5%, and the line the median. These results should not
be interpreted as a probability distribution, but an assessment of the variation in optimum vac-
cination age given parameter uncertainty.
Fig 5B shows the effect of vaccinating at different ages (coverage fixed at 70%) with the
parameter values used in the sensitivity analysis. We consider the proportion of parameter sets
that maximize the probability of having more than 80% reduction in hospitalisations (black
Table 2. Model parameters that have been included in the sensitivity analysis, their upper and lower bounds and their probability density
functions.
Parameter Symbol Lower and upper limits Probability density function (pdf)
Duration of primary infection γ0 [4–10] days Triangular with peak at 9 day
Duration of second and subsequent infections γ1,γ2 [1–5] days Triangular with peak at 4 days
Duration of short term protection ρ0,ρ1,ρ2 [2–17] months Triangular with peak at 6 months
Reduction in susceptibility after ﬁrst infection σ1 [0–1] Triangular with peak at 0.75
Reduction in susceptibility after second infection σ2 [0–1] Triangular with peak at 0.65
Reduction in infectiousness of secondary and tertiary infections α1,α2 [0–1] Uniform
doi:10.1371/journal.pone.0138018.t002
Vaccine Induced Herd Immunity for Control of RSV
PLOSONE | DOI:10.1371/journal.pone.0138018 September 21, 2015 8 / 16
line) or ones than minimize the probability of having less than 40% reduction (blue line). The
red dots shows that the highest proportion of 80% reduction is achieved with a vaccine given at
age 10 months while the lowest proportion of a 40% reduction is achieved with a vaccine given
at age 5 months. This result demonstrates that there is considerable variability in the potential
effectiveness of a vaccination programme when both parameter and structural uncertainty are
included, but that the age range of optimum outcome is relatively narrow.
Discussion
We have presented an analysis of a mathematical model describing the transmission dynamics
of RSV using data from a low-income country setting and explored both the long-term and the
short-term impact of introducing RSV immunisation with two mixing assumptions. The out-
come of fitting the model with different mixing assumptions gives results that are indistinguish-
able in terms of model fit and broadly consistent results in terms of the impact of immunisation.
However, the results differ in a number of respects. First, there is a narrower range for the opti-
mum age for the synthetic matrix, and the predicted impact is generally lower. Second, the two
matrices are associated with very different underlying seasonal patterns of transmission. In fact
the seasonal forcing that explains the observed epidemic pattern of RSV depends heavily on the
details of theWAIFW. This is to be expected, and something worth exploring in more detail. If
children are the “core group” for RSV as they are for measles [36], then presumably contact pat-
terns are seasonally forced by the school year pattern, which is known, and would provide indi-
rect information on theWAIFWmatrix. Because the fitted dynamics of infection vary
considerably depending on theWAIFW structure, but the optimum age window is unchanged,
we suggest that this result will hold for most other epidemiological settings. Consideration of
the impact of demographics and mixing in other settings remain to be explored.
From Fig 3, it is clear that vaccination is potentially effective if given after maternal immu-
nity is lost and before individuals have been infected for the first time. This is a restatement of
Fig 3. The effect of different ages at immunisation for different coverage with the base parameter set (Table 1) for the diary (A) and synthetic (B)
contact matrices. The contour plots show the proportions of hospitalisations prevented by immunisation at different coverage (x-axis) by age at
immunisation (y-axis) calculated over a 10 year time after transients have died away.A) diary WAIFW, estimated duration in M class, 2.3m.B) synthetic
mixingWAIFW, estimated duration in M class 4.0m. In A, the most hospitalisations are prevented by vaccination at ~11m, and in B at ~6m.
doi:10.1371/journal.pone.0138018.g003
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the ‘window problem’ first recognized for measles in high transmission settings [35], but with
the extension that for RSV all settings are essentially high transmission because people are
often reinfected [14, 15, 22, 37].
Further explanation for the impact of such immunisation is portrayed in Fig 4, which shows
that immunisation works rapidly and effectively to reduce hospitalisation since severe disease is
highly age-dependent (see Table A in S1 File). However, the dynamic patterns predicted for the
mixing matrices are different. TheWAIFWmatrix derived from contact diaries predicts an initial
dramatic decline in cases as virus circulation is almost stopped for the first few epidemic seasons.
As with other infections, this results in a build-up of susceptibles and a subsequent rebound of
epidemics [35]. Although virus circulation returns in older age groups, the immunisation pro-
gramme prevents a return to pre-vaccination levels of disease. TheWAIFWmatrix derived syn-
thetically allows virus transmission to be maintained and precludes a rebound effect. Given that
viral circulation is not predicted to be greatly curtailed, there is very little possibility of adverse
consequences of immunisation, for example caused by increased susceptibility in adults.
Fig 4. The impact of vaccination on infection and disease predicted using the diary (blue lines) and synthetic (red lines) WAIFWmatrices and base
parameter set. A) the short term temporal effect of vaccination pre and post immunization with vaccination implemented at time 0. B) the total impact (solid
lines) and the direct effect (dashed lines) of vaccination with a vaccine given at 6 months for different coverages; blue and red lines the diary and synthetic
model respectively. C-D) the age specific FOI at equilibrium pre-vaccination (solid) and with vaccination at 6 months at 70% coverage (dashed). E) the
change in the average age at primary (solid line) and secondary (dashed line) with a vaccine given at 6 months of age.
doi:10.1371/journal.pone.0138018.g004
Vaccine Induced Herd Immunity for Control of RSV
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The two mixing matrices also predict two different mechanisms for vaccination effective-
ness. Using the diary matrix, the model is essentially a susceptible-infected-resistant (SIR)
framework in which primary cases drive the transmission and re-infections are “followers”, i.e.
if the primary cases are reduced, then circulation is suppressed. Vaccination results in a dra-
matically increased average age at first infection (Fig 4E), effectively reducing the risk of infants
becoming infected during the most susceptible ages. Using the synthetic matrix, reinfections
are more important sources of transmission, so that transmission continues in the face of vacci-
nation. Contact patterns are dominated by children (compare Fig 4C and 4D), so the indirect
protection comes from preventing the young infecting the very young, i.e. it is more dependent
on the exact contact pattern between the youngest age groups. Vaccination is predicted to
delay, rather than prevent, primary infection, so that the increase in average age at primary
infection is relatively small, but has a large impact. The estimate of viral transmissibility (as
measured by the basic reproduction number) using the diary approach is below that using the
synthetic matrix, and the two models (same structure, different parameters) fall either side of
the re-infection threshold [37, 38]. For the diary matrix, RSV is unable to persist on secondary
and tertiary infections alone, whereas the synthetic matrix model does not require primary
infections to persist. Note the relative infectiousness of the different stages is fixed, but the
overall infectiousness is estimated given the different mixing structures. This yields very differ-
ent estimates for the basic reproduction numbers for the two models, even though they fit the
data equally well prior to vaccination.
These observations make our vaccination results doubly robust: either primary cases are the
drivers of RSV and transmission is greatly reduced, or primary cases are less important but vac-
cination reduces the source of transmission to the most vulnerable age groups. In either case
we are predicting a substantial benefit from vaccination, with 50–70% of reduction in hospitali-
sation due to indirect protection.
Fig 5. Sensitivity analyses. A: the median impact of vaccination in terms of proportion of RSV hospital admissions averted at 70% coverage at different
ages with the bars showing the 95% range of results. The red dot indicates the highest median predicted impact (63% at 6m). B) the optimal age to vaccinate
if the objective is to maximize the proportion of >80% reduction (black line) or minimize the proportion of <40% reduction (blue). The red dot shows the month
at which the highest proportion of 80% reduction or the lowest proportion of 40% reduction is achieved on the black and blue lines respectively.
doi:10.1371/journal.pone.0138018.g005
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The uncertainty and sensitivity results demonstrate that there is considerable variability in
the potential effectiveness of a vaccination programme when both parameter and structural
uncertainty are included. Given available information, the impact of 70% coverage could be to
reduce hospitalisations by any value between 10% and 90%, although the best median values
are>60%. However, the age of optimum immunisation is robust to these uncertainties.
Whether the objective is to maximise the chances of a very successful intervention (>80%
reduction in hospitalisation), reduce the chances of a poor intervention (<40% reduction) or
maximise the expected outcome, the age window remains 5m to 10m.
The correlation between model outcomes and unknown parameters shows that the two
models differ in their sensitivity. The diary matrix model emphasizes infection transmission
between younger age groups (i.e. infants infected from primary infections), whereas the syn-
thetic matrix emphasizes infection from older individuals (i.e. from secondary and subsequent
infections to infants). Our focus has been on the impact of vaccination, but we have also dem-
onstrated that the prediction of infection dynamics and consequent impact of immune
responses to infection depends critically on the mixing assumptions. Recent results have also
demonstrated the importance of demographic processes (especially birth rate) [39], and envi-
ronmental (atmospheric) conditions [40] in determining RSV transmission dynamics. Recent
individual-based models including explicit household and school-based transmission comes to
a similar conclusion to our own [41]. Similarly, the impact of vaccination has been shown to be
beneficial in much simpler models (e.g. [42]). Clearly, the impact of vaccination needs to be
assessed in a wide variety of models including these and other processes such as viral genetics
[34], but no model has yet suggested that immunisation against RSV would not be beneficial.
Immunisation is an extremely effective tool for preventing infection in individuals, but also
results in protection of those not immunised through herd immunity. Careful consideration of
the effects of herd immunity often changes the optimum allocation of vaccine [43–45]. Our
results indicate that immunisation of young children (5–10m) is likely to be a highly effective
method of prevention of severe RSV disease which arises predominately from infection in
infants<6m old. The majority benefit is derived from herd immunity. We are greatly reassured
that the different WAIFW, seasonality and reinfection threshold parameters can be combined
to give the same endemic pattern and predict a similar public health benefit to vaccination.
Given the scarcity of contact data in different populations and the costly nature and diffi-
culty of acquiring such data, we have developed a computational approach to derive the mixing
pattern of the KHDSS population from household contacts combined with assumptions about
school and out-of-school mixing pattern. This kind of approach has been independently devel-
oped for a number of European countries [46] with a notable agreement between the synthetic
and the contact diary mixing data generated from the POLYMOD study [47]. The main advan-
tage with this method is that it is general and can be easily used for regions without contact sur-
vey data as well as reconstruction of historical contact patterns for evaluation of the effect of
demographic transition.
The vaccine modelled here only protects against primary infection. Importantly, this
assumes that, as with primary infection, vaccination is followed by a transient period of protec-
tion and subsequent reduced susceptibility to reinfection and reduced infectiousness and dura-
tion upon reinfection. Although this is the most likely scenario for LAV since boosting of titres
is absent in seropositives [4], reversion to a completely naïve susceptible state following waning
vaccine immunity (or indeed natural infection immunity) cannot be ruled out [34]. Given that
our results are dependent on reduction in disease rather than infection, a vaccine that reduces
infectiousness of secondary and subsequent infections would have no less impact, but may be
higher. Additionally, this work provides a conservative estimate of the impact of vaccination in
assuming that the vaccine acts only on naïve individuals i.e. not previously infected. This
Vaccine Induced Herd Immunity for Control of RSV
PLOSONE | DOI:10.1371/journal.pone.0138018 September 21, 2015 12 / 16
would be the situation for a highly attenuated live virus vaccine that would not boost antibody
in seropositive susceptibles.
We argue that RSV vaccine in 5–10m old children would result in significant herd immu-
nity and lead to marked reduction in disease in those<6 months old. There are a group of vac-
cines that have already been subject to extensive trials and have relatively few obstacles
remaining to develop an effective licensed product. We therefore propose that promotion of
these candidates could have clear global public health benefit.
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